Lee Graves

Dr. Graves is a professor at the University of North Carolina, Chapel Hill, and has more than 25 years of experience studying protein kinases, cell signaling, and applying proteomics. He holds a BS in Biochemistry from Iowa State University, a Ph.D. in Biochemistry from the University of Illinois, and a postdoctoral degree in Pharmacology from the University of Washington.

Dr. Graves' lab uses kinase inhibitor bead affinity chromatography and quantitative mass spectrometry methods to examine changes in the kinome 'en masse from kinase inhibitor-treated cells, Ras knockdown cells, virally infected cells, and brain samples. In collaboration with Madera Therapeutics, Dr. Graves applied a chemical proteomics approach and discovered ClpP as a novel drug target for ONC201 and the optimized TR compounds (Graves et al., 2019).